Terms: = Thyroid cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
24 results:
1. Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.
Ni Z; Cong S; Li H; Liu J; Zhang Q; Wei C; Pan G; He H; Liu W; Mao A
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):255-269. PubMed ID: 38186223
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract] [Full Text] [Related]
3. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract] [Full Text] [Related]
4. The Overexpression of SLC25A13 Predicts Poor prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.
Lv Y; Yuan CH; Han LY; Huang GR; Ju LC; Chen LH; Han HY; Zhang C; Zeng LH
Dis Markers; 2022; 2022():4091978. PubMed ID: 35607442
[TBL] [Abstract] [Full Text] [Related]
5. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract] [Full Text] [Related]
6. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated thyroid cancer: The REALITY Randomized Clinical Trial.
Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
[TBL] [Abstract] [Full Text] [Related]
7. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract] [Full Text] [Related]
8. Anlotinib in Locally Advanced or Metastatic Medullary thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract] [Full Text] [Related]
10. A Novel Multimodal Therapy for Anaplastic thyroid Carcinoma:
Niu Y; Ding Z; Deng X; Guo B; Kang J; Wu B; Fan Y
Front Endocrinol (Lausanne); 2020; 11():207. PubMed ID: 32390940
[TBL] [Abstract] [Full Text] [Related]
11. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting vegfr2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract] [Full Text] [Related]
12. PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/vegfr2 Pathway in Papillary thyroid Carcinoma.
Chen Q; Yu WY; Zhang HH; Zhang SZ; Fang J; Wu F; Ying HZ; Yu CH
Biomed Res Int; 2020; 2020():8954513. PubMed ID: 32047817
[TBL] [Abstract] [Full Text] [Related]
13. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and vegfr2.
Grüllich C
Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
[TBL] [Abstract] [Full Text] [Related]
14. Apatinib: A Review in Advanced Gastric cancer and Other Advanced cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of lenvatinib in treating thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
[TBL] [Abstract] [Full Text] [Related]
16. thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome.
Wood LW; Cox NI; Phelps CA; Lai SC; Poddar A; Talbot C; Mu D
Sci Rep; 2016 Feb; 6():19857. PubMed ID: 26912193
[TBL] [Abstract] [Full Text] [Related]
17. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract] [Full Text] [Related]
18. Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Wunderlich A; Khoruzhyk M; Roth S; Ramaswamy A; Greene BH; Doll D; Bartsch DK; Hoffmann S
J Surg Res; 2013 Dec; 185(2):676-83. PubMed ID: 23845866
[TBL] [Abstract] [Full Text] [Related]
19. Papillary thyroid carcinoma involving cervical neck lymph nodes: correlations with lymphangiogenesis and ultrasound features.
Choi Y; Park KJ; Ryu S; Kim DH; Yun J; Kang DK; Chun M
Endocr J; 2012; 59(10):941-8. PubMed ID: 22785182
[TBL] [Abstract] [Full Text] [Related]
20. [Vascular endothelial growth factor (VEGF) in endocrinology and oncology].
Kajdaniuk D; Marek B; Fołtyn W; Kos-Kudła B
Endokrynol Pol; 2011; 62 Suppl 3():14-22. PubMed ID: 22161982
[TBL] [Abstract] [Full Text] [Related]
[Next]
